Active programs
Studies in flight.
Qvin runs alongside academic and industry collaborators on the studies that turn the Q-Pad's analytical surface into clinical evidence. Below: the named programs we can talk about publicly, plus a forward-looking view of the additional studies in early stages.
Cervical cancer · STIs · BV
HR-HPV — clinical validation on a regulated molecular platform.
Qvin's most advanced clinical program: validation of high-risk HPV detection from menstrual blood collected on the Q-Pad, running on a regulator-cleared molecular diagnostics platform whose existing HR-HPV assay is FDA-approved. An IRB-approved multi-site clinical study collects paired Q-Pad and clinician-collected endocervical samples in colposcopy patients. The aim is regulatory clearance of the assay on the Q-Pad sample type, opening at-home cervical cancer screening on a molecular platform already trusted by clinicians.
Status: analytical studies largely complete; clinical validation in progress.
Industry partner: leading global molecular diagnostics platform with an FDA-approved HR-HPV assay (named under MTA; not disclosed publicly).
Clinical-site detail: specific trial sites are reserved until individually cleared for public disclosure.
Endometriosis
Endometriosis — diagnostic development.
A diagnostic-development program exploring inflammatory and tissue-specific biomarkers of endometriosis in menstrual blood. Endometriosis is a disease of misplaced endometrial tissue — and menstrual blood is the only routinely available clinical sample that contains intact endometrial tissue from the patient. The program is currently in diagnostic-development phase with the goal of supplementing or substituting today's surgical workup.
Status: active — diagnostic development phase.
Clinical question: non-invasive aid-in-diagnosis of endometriosis without surgical workup.
Institutional lead: reserved until individually cleared for public disclosure.
Menopause transition
Longitudinal menopause cohort.
A longitudinal cohort study tracking hormonal change through the menopause transition. The clinical question: what does a recurring, multi-cycle hormonal record from menstrual blood — FSH, LH, estradiol, AMH, TSH — reveal about perimenopause that a single venous draw cannot? The answer compounds over time; the longer the cohort runs, the more valuable the dataset becomes, both clinically and as a reference resource.
Status: active — longitudinal enrollment.
Clinical question: longitudinal multi-axis hormonal monitoring across the perimenopausal window.
Institutional lead: reserved until individually cleared for public disclosure.
Heavy menstrual bleeding
HMB — methylation and genomic-association discovery.
An active discovery program using DNA methylation and broad genomic association across millions of loci, with planned extension into RNA-based assays. The program runs on the full Qvin lab package — including the biobanking module — creating a reusable menstrual-blood biobank rather than a one-time dataset. The strategic prize is reducing time-to-effective-treatment for HMB, where today's standard of care is symptom-based.
Status: active — methylation analysis in progress; RNA extension planned.
Institutional lead and funder: reserved until individually cleared for public disclosure.
Perimenopause biomarkers
Perimenopause biomarkers.
An additional program focused on perimenopause biomarkers and the perimenopausal transition. Most women navigate perimenopause without longitudinal biomarker data because hormonal levels fluctuate cycle-to-cycle and a single venous draw is uninformative. The Q-Pad's recurring at-home format is what longitudinal hormonal monitoring across the transition has lacked. The clinical end-point is a longitudinal home-collection panel that supports clinicians and patients with evidence rather than guesswork.
Status: active — biomarker discovery and validation.
Institutional lead and funder: reserved until individually cleared for public disclosure.
Forthcoming
Additional programs.
Several additional studies are at earlier stages — under MTA negotiation, in IRB review, or in pre-launch protocol development. Collaborator names are reserved until launch. The shape of the forward pipeline:
| Condition area | Stage | Expected start |
|---|---|---|
| Endometriosis (additional partner) | Exploratory · MTA stage | Forthcoming |
| Hormones & fertility | Early-stage discussion · consumer/research channel | Forthcoming |
| Endometrial cancer | Discovery · institutional partner under discussion | Forthcoming |
| Multi-omics reference dataset | Cross-cutting — see Conditions overview for platform-layer context | Active |
Programs marked "Forthcoming" are subject to study-protocol approval, IRB review, and partner sign-off. We update this table as studies launch.
Working with us
Want to start a program?
Academic institutions and research groups: see Commercial → Research partnerships for what we provide and how we structure collaborations. Industry counterparties exploring assay co-development: Commercial → Industry partnerships. Direct: soren@qvin.com.